Advertisement

Table of Contents

February 11, 2016; 127 (6)

BLOOD FLASHBACK

INSIDE BLOOD COMMENTARIES

PLENARY PAPER

REVIEW ARTICLE

HOW I TREAT

CLINICAL TRIALS AND OBSERVATIONS

  • Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
    Michael W. Deininger, J. Graeme Hodgson, Neil P. Shah, Jorge E. Cortes, Dong-Wook Kim, Franck E. Nicolini, Moshe Talpaz, Michele Baccarani, Martin C. Müller, Jin Li, Wendy T. Parker, Stephanie Lustgarten, Tim Clackson, Frank G. Haluska, Francois Guilhot, Hagop M. Kantarjian, Simona Soverini, Andreas Hochhaus, Timothy P. Hughes, Victor M. Rivera and Susan Branford
  • Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
    Paul G. Richardson, Vânia T. M. Hungria, Sung-Soo Yoon, Meral Beksac, Meletios Athanasios Dimopoulos, Ashraf Elghandour, Wieslaw W. Jedrzejczak, Andreas Guenther, Thanyaphong Na Nakorn, Noppadol Siritanaratkul, Robert L. Schlossman, Jian Hou, Philippe Moreau, Sagar Lonial, Jae Hoon Lee, Hermann Einsele, Monika Sopala, Bourras-Rezki Bengoudifa, Claudia Corrado, Florence Binlich and Jesús F. San-Miguel

IMMUNOBIOLOGY

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

THROMBOSIS AND HEMOSTASIS

BLOOD WORK